Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes

Tumor-associated macrophages (TAMs) exist in nearly all tumors, and form a major part of the tumor microenvironment . TAMs are divided into two groups: tumor-suppressing M1 type tumor-promoting M2 type. Most educated by cells to become type, which support growth make immunotherapy ineffective. Antibody-dependent cellular phagocytosis (ADCP) is an important mechanism for antibody cancer therapy, this dependent on TAMs. In study, we found that elicit more efficient ADCP response than was confirmed three cell lines, Raji, A431, SKBR3, along with their corresponding therapeutic Rituximab , anti-EGFR mouse monoclonal (clone 528), Trastuzumab respectively. Resiquimod (R848), immune system activating agent, has been shown stimulate macrophages, re-educate from By treating R848, increased significantly vitro vivo xenograft models. R848 encapsulated liposomes (R848-LPs) not only accumulated efficiently tissues, but also distributed Synergizing R848-LPs 528) inhibited WiDr-tumor Our study revealed TAM-targeted delivery able enhance effect antibodies, hence, anti-tumor antibodies.